Wells Fargo Downgrades Akcea Therapeutics, Inc. (AKCA) to Equal Weight, Following Acquisition

August 31, 2020 11:38 AM EDT
Get Alerts AKCA Hot Sheet
Price: $18.17 --0%

Rating Summary:
    1 Buy, 4 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 18 | Down: 26 | New: 11
Trade Now! 
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.

Wells Fargo analyst Jim Birchenough downgraded Akcea Therapeutics, Inc. (NASDAQ: AKCA) from Overweight to Equal Weight.

For an analyst ratings summary and ratings history on Akcea Therapeutics, Inc. click here. For more ratings news on Akcea Therapeutics, Inc. click here.

Shares of Akcea Therapeutics, Inc. closed at $11.38 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Downgrades

Related Entities

Wells Fargo